Sold as Ruxolitinib. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 15, 2026, FDA lists 3 applications for Ruxolitinib (sold as Ruxolitinib), with 0 new uses approved and 0 published complete response letters.
| Jaktinib in Ruxolitinib-Treatment Failure Myelofibrosis: A Multicenter, Prospective, Real-World Observational StudyMyeloproliferative Neoplasms/Myelofibrosis · Affiliated Hospital of Nantong University | — | Not yet recruiting | Nov 9, 2026 |
| A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)Transplant Failure or Rejection of Bone Marrow (Graft vs Host Disease, GVHD) · Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Nov 3, 2026 |
| Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized VitiligoVitiligo, Nonsegmental Vitiligo · Kafrelsheikh University | Not applicable | Enrolling by invitation | Nov 2, 2026 |
| A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative NeoplasmsMyeloproliferative Neoplasms (MPNs) · Damora Therapeutics | Phase 1 | Recruiting | Sep 30, 2026 |
| Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP TrialCarcinoma, Squamous Cell of Head and Neck HNSCC · University Hospital, Basel, Switzerland | Phase 2 | Not yet recruiting | Sep 25, 2026 |
| Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)Acute Skin Graft Versus Host Disease (GVHD) · Children's Hospital Medical Center, Cincinnati | Phase 1 | Not yet recruiting | Sep 3, 2026 |
| Evaluating Safety ,Tolerability, Pharmacokinetic,Efficacy of WJ01024 or WJ01024 Combined With Ruxolitinib in Patients With MyelofibrosisMF With Splenomegaly · Henan Cancer Hospital | Phase 1 | Recruiting | Sep 3, 2026 |
| Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNIAcute Leukemia, Myelodysplastic Syndromes · Peking University People's Hospital | Phase 1 / Phase 2 | Not yet recruiting | Sep 1, 2026 |
| — | RuxolitinibANDA 208869 | Apotex Inc | 0 | Discontinued |
| — | RuxolitinibANDA 220375 | Torrent Pharmaceuticals Ltd | 0 | Discontinued |
| — | RuxolitinibNDA 219660 | Apotex | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Apotex